Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) (NCT06073821)

🧪 Interventions in This Study

• Sonrotoclax (DRUG)
• Zanubrutinib (DRUG)
• Venetoclax (DRUG)
• Obinutuzumab (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
2. Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
3. Measurable disease by Computer Tomography/Magnetic Resonance Imaging
4. Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin \< 3.0 x ULN
5. Adequate renal function as defined as creatinine clearance ≥ 50 milliliters per minute

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (201 Sites)

Showing the first 25 of 201 sites.

• Alaska Oncology and Hematology, Llc — Anchorage, Alaska
• City of Hope National Medical Center — Duarte, California
• University of California San Diego (Ucsd) Moores Cancer Center — La Jolla, California
• Valkyrie Clinical Trials — Los Angeles, California
• UCLA Department of Medicine Hematologyoncology — Los Angeles, California
• Chao Family Comprehensive Cancer Center — Orange, California
• Stanford Medicine — Palo Alto, California
• University of Colorado Cancer Center — Aurora, Colorado
• Medstar Georgetown University Hospital — Washington D.C., District of Columbia
• Mount Sinai Medical Center Braman Comprehensive Cancer Center — Miami, Florida
• Moffitt Cancer Center — Tampa, Florida
• Southeastern Regional Medical Center — Newnan, Georgia
• Northwestern University — Chicago, Illinois
• Illinois Cancercare, Pc — Peoria, Illinois
• Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
• University of Iowa Hospitals and Clinics — Iowa City, Iowa
• Mission Cancer and Blood — Waukee, Iowa
• The University of Kansas Cancer Center — Westwood, Kansas
• Norton Cancer Institute Pavilion — Louisville, Kentucky
• Ochsner Clinic Foundation — New Orleans, Louisiana
• University of Minnesota — Minneapolis, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• John Theurer Cancer Center Hackensack University Medical Center — Hackensack, New Jersey
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
• Columbia University Medical Center — New York, New York

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in CLL

• A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors — Jonesboro, Arkansas
• Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL — New Haven, Connecticut

Explore by condition: All CLL clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.